Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

MAgicTouch™ Intervention Leap for Dialysis Access (MATILDA) Trial (MATILDA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04698512
Recruitment Status : Completed
First Posted : January 7, 2021
Last Update Posted : March 17, 2021
Information provided by (Responsible Party):
Singapore General Hospital

Brief Summary:
For patients with End Stage Renal Failure (ESRF), the surgical creation of an Autogenous Arteriovenous Fistula (AVF) or Autogenous Arteriovenous Graft (AVG) is the recognised standard for providing vascular access. A functioning dialysis vascular access is essential to facilitate hemodialysis (HD) treatment. Advantages include improved hemodialysis initiation time, improved dialysis quality, better maintenance of accesses and generally, better outcomes in patients. Unfortunately almost 50% of AVF and AVG fail after a median lifetime of 3 to 7 years and 12 to 18 months respectively. Vascular access dysfunction is a major cause of morbidity and hospitalisation for ESRF patients, costing the healthcare system USD 18 million globally. Venous stenosis and scarring are caused by trauma from surgical access creation when the circuit comes arterialized and from repeated percutaneous punctures from subsequent hemodialysis. This study is performed to evaluate Sirolimus-coated balloon efficacy and safety using MagicTouch™ Drug coated balloon catheter (Concept Medical Inc, Tampa, FL, US) on AVF patency with de novo and recurrent stenosis.

Condition or disease Intervention/treatment
Dialysis Access Malfunction End Stage Renal Failure on Dialysis End Stage Renal Disease Fistulas Arteriovenous Stenosis Device: AVFistuloplasty with Sirolimus coated balloon

Layout table for study information
Study Type : Observational [Patient Registry]
Actual Enrollment : 35 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 12 Months
Official Title: MAgic Touch™ Intervention Leap for Dialysis Access (MATILDA) Trial
Actual Study Start Date : May 21, 2019
Actual Primary Completion Date : January 16, 2020
Actual Study Completion Date : January 30, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dialysis
Drug Information available for: Sirolimus

Group/Cohort Intervention/treatment
Arteriovenous Fistuloplasty with MagicTouch™ Balloon
Patients above the age of 21 that have undergone AVF / AVG fistuloplasty with MagicTouch™ at Singapore General Hospital will be included in the study and followed up post-op for 12 months. Patients will be treated and followed-up following standard clinical care pathways.
Device: AVFistuloplasty with Sirolimus coated balloon
After an initial fistulogram, the lesion will first be predicated with standard high pressure balloon, followed by MagicTouch™ Sirolimus drug coated balloon

Primary Outcome Measures :
  1. Target Lesion Primary Patency [ Time Frame: 3-months post op ]
    No need for clinically driven reintervention of target lesion, no access thrombosis and no significant restenosis (lumen diameter <2.7mm) on duplex ultrasound

  2. Target Lesion Primary Patency [ Time Frame: 6-months post op ]
    No need for clinically driven reintervention of target lesion, no access thrombosis and no significant restenosis (lumen diameter <2.7mm) on duplex ultrasound

  3. Freedom from localised or systemic serious adverse events [ Time Frame: 30 days post-op ]
    Include life-threatening events or those resulting in death, requiring hospitalisation, resulting in permanent disability, or requiring intervention to prevent permanent impairment

Secondary Outcome Measures :
  1. Access circuit patency [ Time Frame: 3 and 6 months post op ]
    Lack of stenosis in any region of the AVF circuit requiring intervention

  2. Procedural success [ Time Frame: Day of operation ]
    Defined as technical success with at least one indicator of hemodynamic or clinical success. I.e. no conduit rupture during any of the procedures requiring bailout stenting.

  3. Primary assisted patency [ Time Frame: 3 and 6 months post op ]
    Lack of access circuit thrombosis requiring thrombolysis

  4. Number of open bypass revision surgery required to maintain access circuit primary patency [ Time Frame: 3 and 6 months post op ]
  5. Secondary access patency [ Time Frame: 3 and 6 months post-op ]
    Lack of dialysis access abandonment

  6. Number of interventions required to maintain access circuit primary patency [ Time Frame: 3 and 6 months post-op ]
  7. Event of mortality [ Time Frame: 6 months post-op ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who have received inpatient treatment (i.e. fistuloplasty) for their failing dialysis access at Singapore General Hospital

Inclusion Criteria:

  • Informed consent was obtained
  • Patient aged ≥ 21 and ≤ 90 years
  • Native AVF was created more than 2 months prior to index procedure and had undergone 10 or more haemodialysis sessions utilizing two needles
  • Target lesion location had to be located between the anastomoses to the axillary-subclavian vein junction, as defined by insertion of the cephalic vein
  • On initial fistulogram, target lesions stenosis had to be ≥50 on angiographic assessment and in keeping with the clinical indicator for intervention
  • Stenosis had to <12cm in length (to allow for potential treatment with one SCB (length 15cm) only
  • Stenosis had to be initially treated successfully with a high-pressure plain balloon prior to SCB treatment as defined by:- (A) no clinically significant dissection (flow limiting) (B) no extravasation requiring treatment/stenting (C) residual stenosis ≤30% by angiographic measurement (D) Ability to completely efface the lesion waist using the pre-dilation balloon
  • No more than one additional ("nontarget") lesion in the access circuit that had to be also successfully treated (≤30% residual stenosis) before drug elution. Separate lesion was defined by at least 3cm in distance from the target lesion.
  • Reference vessel diameter 5mm-8mm

Exclusion Criteria:

  • Women who were preganant, lactating, or planning on becoming pregnant during the study
  • Subject had more than 2 lesions in the access circuit
  • Subject had a secondary non-target lesion that could not be successfully treated
  • Sepsis or active infection
  • Asymptomatic target lesions
  • A thrombosed access or an access with thrombosis treated ≤ 30 days prior to index procedure
  • Surgical revision of the access site performed, planned or expected ≤ 3months before or after the index procedure
  • Patients who were taking immunosuppressive therapy or are routinely taking ≥15 mg prednisone per day
  • Currently participating in another investigational drug, biologic, or device study involving Sirolimus or paclitaxel
  • Contraindication to Aspirin or Clopidogrel usage
  • Mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study, or language barrier such that the subject is unable to give informed consent
  • Uncooperative attitude or potential for non-compliance with the requirements of the protocol making study participation impractical
  • Where final angioplasty treatment requires a stent or drug eluting balloon >8mm in diameter
  • Metastatic cancer or terminal medical condition
  • Blood coagulation disorders
  • Limited life expectancy (<12 months)
  • Allergy or other know contraindication to iodinated media contrast, heparin, or Sirolimus

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04698512

Layout table for location information
Singapore General Hospital
Singapore, Singapore, 169856
Sponsors and Collaborators
Singapore General Hospital
Layout table for investigator information
Principal Investigator: Tjun Yip Tang Singapore General Hospital
Layout table for additonal information
Responsible Party: Singapore General Hospital Identifier: NCT04698512    
Other Study ID Numbers: MATILDA
First Posted: January 7, 2021    Key Record Dates
Last Update Posted: March 17, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Singapore General Hospital:
Sirolimus coated balloon
Target lesion primary patency
Arterio-venous fistula
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Failure, Chronic
Arteriovenous Fistula
Kidney Diseases
Urologic Diseases
Pathological Conditions, Anatomical
Renal Insufficiency, Chronic
Renal Insufficiency
Arteriovenous Malformations
Vascular Malformations
Cardiovascular Abnormalities
Cardiovascular Diseases
Vascular Fistula
Vascular Diseases
Congenital Abnormalities
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs